Vildagliptin (LAF-237) , ≥99% , 274901-16-5

CAS NO.：274901-16-5

Empirical Formula: C17H25N3O2

Molecular Weight: 303.4

MDL number: MFCD08275142

EINECS: 630-410-0

PRODUCT Properties

• Melting point: 153-155?C
• alpha: -78.3° (c = 9.73 in methanol)
• Boiling point: 531.3±50.0 °C(Predicted)
• Density: 1.27
• Flash point: 275.1℃
• storage temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• solubility: Soluble in DMSO (up to 45 mg/ml), in DMF (up to 20 mg/ml), or in Ethanol (up to 20 mg/ml).
• form: solid
• pka: 15.05±0.40(Predicted)
• color: White
• optical activity: [α]/D -81 to -91°, c =0.1 in methanol
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO, DMF, or ethanol may be stored at -20°C for up to 3 months
• InChI: InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
• InChIKey: SYOKIDBDQMKNDQ-XWTIBIIYSA-N
• SMILES: N1(C(CNC23CC4CC(CC(O)(C4)C2)C3)=O)CCC[C@H]1C#N
• CAS DataBase Reference: 274901-16-5(CAS DataBase Reference)

Description and Uses

Vildagliptin, a DPP-4 inhibitor, was launched for the oral treatment of type 2 diabetes. Vildagliptin is the second DPP-4 inhibitor to reach the market behind sitagliptin, which was introduced in 2006. DPP-4 inhibitors act by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase the synthesis and release of insulin from pancreatic βcells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic α cells, which leads to reduced hepatic glucose production. However, although GLP-1 and GIP effectively lower blood glucose, they are short-lived as a result of rapid inactivation by the ubiquitous serine protease DPP-4. By inhibiting DPP-4, vildagliptin increases the concentration and duration of active incretin levels, which in turn results in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Both vildagliptin and sitagliptin are potent, competitive, reversible inhibitors of DPP- 4 (IC₅₀=3.5 and 18 nM, respectively), and they both show slow, tight-binding inhibition kinetics.

The major metabolite of Vildagliptin

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H332-H335
• Precautionary statements: P261-P280-P305+P351+P338
• Risk Statements: 28-38-41-48
• Safety Statements: 24/25-26-28-36/37/39
• RIDADR: 3077
• HS Code: 29339900